CLINICAL TRIALS PROFILE FOR TIDEGLUSIB

Clinical Trials for Tideglusib

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00948259 ↗	Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease	Completed	Noscira SA	Phase 1/Phase 2	The purpose of this study is to evaluate if 4 escalating doses during 20 weeks of NP031112 are safe and tolerated in patients with Alzheimer´s disease.
NCT01049399 ↗	Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy	Completed	i3 Research	N/A	The purpose of this study is to determine wether NP031112 is safe and effective in the treatment of mild to moderate Progressive Supranuclear Palsy
NCT01049399 ↗	Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy	Completed	Noscira SA	N/A	The purpose of this study is to determine wether NP031112 is safe and effective in the treatment of mild to moderate Progressive Supranuclear Palsy
NCT01350362 ↗	Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients	Completed	ICON Clinical Research	Phase 2	The main purpose of this study is to evaluate the cognitive changes after administration of tideglusib versus placebo at two oral doses and two treatment regimes for 26 weeks in patients with mild to moderate Alzheimer's disease. After the 26 week core treatment period, the patients may continue in the study under blinded conditions for an optional extension period up to a maximum of 39 additional weeks (total study duration up to 65 weeks), until the last patient in the study has completed the 26 week of treatment.
NCT01350362 ↗	Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients	Completed	Noscira SA	Phase 2	The main purpose of this study is to evaluate the cognitive changes after administration of tideglusib versus placebo at two oral doses and two treatment regimes for 26 weeks in patients with mild to moderate Alzheimer's disease. After the 26 week core treatment period, the patients may continue in the study under blinded conditions for an optional extension period up to a maximum of 39 additional weeks (total study duration up to 65 weeks), until the last patient in the study has completed the 26 week of treatment.
NCT02586935 ↗	Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders	Completed	Holland Bloorview Kids Rehabilitation Hospital	Phase 2	This study will examine the safety and efficacy of tideglusib vs. placebo for the treatment of core symptom domains in adolescents with Autism Spectrum Disorders

Clinical Trial Conditions for Tideglusib

Condition Name

Condition Name
Intervention	Trials
Congenital Myotonic Dystrophy	2
Myotonic Dystrophy 1	1
Progressive Supranuclear Palsy	1
Alzheimer´s Disease	1

Condition MeSH

Condition MeSH
Intervention	Trials
Myotonic Dystrophy	3
Alzheimer Disease	2
Motor Neuron Disease	1
Supranuclear Palsy, Progressive	1

Clinical Trial Locations for Tideglusib

Trials by Country

Trials by Country
Location	Trials
United States	16
Canada	10
United Kingdom	4
Germany	3
Spain	2

Trials by US State

Trials by US State
Location	Trials
California	3
Virginia	2
New York	2
Iowa	2
Arkansas	2

Clinical Trial Progress for Tideglusib

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 2/Phase 3	2
Phase 2	5
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	5
Not yet recruiting	2
Recruiting	1

Clinical Trial Sponsors for Tideglusib

Sponsor Name

Sponsor Name
Sponsor	Trials
AMO Pharma Limited	3
Noscira SA	3
Canadian Institutes of Health Research (CIHR)	1

Sponsor Type

Sponsor Type
Sponsor	Trials
Other	18
Industry	8